Eculizumab is a biologic therapy, a complement C5 inhibitor, and has recently shown promise in COVID-19. The graph provides an important step towards elucidating the MoA of this drug in COVID-19. Explore the live graph.
Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndrome
